Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer #SGO2025 #gynsm #oncology www.onclive.com/view/dual-pd...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor, according to research presented at #SGOMtg by Dr Hyun-Woong Cho of Korea University. #SGO2025 #gyncsm shorturl.at/b0R0n

Pembro + chemo followed by pembro-olaparib maintenance ± bevacizumab improved PFS vs chemo ± bevacizumab in patients with advanced ovarian cancer in the KEYLYNK-001 trial. Presented at #SGOMtg by Dr Matthew Powell of @washumedicine.bsky.social. #SGO2025 #gyncsm shorturl.at/k5Frm

Luveltamab tazevibulin demonstrated activity in a phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer. Data were presented at #SGOMtg by Jung-Yun Lee of Yonsei University College of Medicine. #SGO2025 #gyncsm shorturl.at/v1Vrz

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/pamipar...

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer @danafarber.bsky.social #SGOMtg #SGO2025 #gyncsm
www.onclive.com/view/rina-s-...

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer #SGO2025

www.onclive.com/view/avutome...

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer #SGO2025 #SGOMtg #gyncsm

www.onclive.com/view/dostarl...

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
#SGO2025 #SGOMtg #gyncsm
www.onclive.com/view/real-wo...

Neoadjuvant nivolumab has demonstrated efficacy in patients with dMMR, surgically resectable endometrial cancer, according to data presented at #SGOMtg by Dr Yong Jae Lee of Yonsei University College of Medicine. #SGO2025 #gyncsm shorturl.at/rHZjS

Mirvetuximab soravtansine improved OS vs chemo in patients with FRα+, platinum-resistant ovarian cancer in the MIRASOL trial. Data were presented at #SGOMtg by Dr Toon Van Gorp of @uzleuven.bsky.social. #SGO2025 #gyncsm shorturl.at/n4n3o

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/metform...

Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.

Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC @mdanderson.bsky.social #SGO2025
www.onclive.com/view/pembrol...

"Matt Hellmann [VP Early Oncology Dev] told @endpts.com
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025

AstraZeneca reveals first-in-human data for B7-H4-targeting ADC in endometrial cancer AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early s...

The 2.4 mg/kg dose hit a 38.5% ORR, according to data presented Saturday at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Seattle. #SGO2025 #gynsm endpts.com/astrazeneca-...

Pembrolizumab Provides Long-Term Benefits in Cervical Cancer Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer.

Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer in the KEYNOTE-A18 trial, presented at #SGOMtg by Dr Linda Duska of @uvahealth.bsky.social. #SGO2025 #gyncsm shorturl.at/shcSW

Antibody-Drug Conjugate Proves Active in Ovarian Cancer A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer.

DB-1305/BNT325 demonstrated durable activity in patients with previously treated ovarian cancer, according to data presented at #SGOMtg by Dr Maria Rubinstein of @mskcancercenter.bsky.social. #SGO2025 #gyncsm shorturl.at/tA2bw

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer #SGOMtg #SGO2025 #ovca

www.onclive.com/view/frontli...

CRT No Better Than RT as Adjuvant Therapy in Early Cervical Cancer Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

Adjuvant CRT does not improve outcomes vs adjuvant RT in intermediate-risk, early-stage cervical cancer, according to phase 3 data presented at #SGOMtg by Dr Sang Young Ryu of the Korea Cancer Center Hospital. #SGO2025 #gyncsm shorturl.at/cYuYj

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer @pennmedicine.bsky.social #gyncsm #SGOMtg #SGO2025
www.onclive.com/view/cyclin-...

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer #SGOMtg #AM25IMPACT #SGO2025 #oncology #gyncsm
www.onclive.com/view/zimbere...

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm #oncology
www.onclive.com/view/afurese...

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 www.onclive.com/view/olapari...

We’re diving into our first full day of #SGO2025, starting with this morning's plenary session on maximizing therapeutic benefit through targeted strategies and predictive assays.

Want to share your expert take? Contact us to schedule an interview! #SGOMtg #gynsm

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer @uvahealth.bsky.social #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/pembrol...

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/cadonil...

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/nivolum...

Good morning Seattle! 🌆

☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!

#SGOMtg #AM25IMPACT #gynsm